Sells reinforced tissue matrices for hernia repair and abdominal wall reconstruction, plus soft-tissue repair products for plastic and reconstructive surgery, to hospitals and ambulatory surgery centers.
10-K for FY2025, filed Mar 25, 2026Our first portfolio of products, the OviTex Reinforced Tissue Matrix (“OviTex”) which we first commercialized in the U.S. in July 2016 and…View ↗
Our OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and…View ↗
Our second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, (“OviTex PRS”) which we first commercialized in the U.S. in May…View ↗
The majority of our products are shipped directly from Auckland, New Zealand to our headquarters in Malvern, Pennsylvania. We sell our…View ↗
Hospitals and other surgical facilities buy products outright. The company is paid when non-consigned products ship or are delivered, and when consigned products are used in a procedure.
10-K for FY2025, filed Mar 25, 2026A significant portion of the Company’s revenue is generated from product shipped to a customer or from consigned inventory maintained at…View ↗
F-12 when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is…View ↗
The majority of our products are shipped directly from Auckland, New Zealand to our headquarters in Malvern, Pennsylvania. We sell our…View ↗
$80.3M
10-K for FY2025, filed Mar 25, 2026
$80.3M ↗
Sells directly to hospitals and ambulatory surgery centers; outside Europe, it does not use stocking distributors. In Europe, it also sells through distributors.
10-K for FY2025, filed Mar 25, 2026
No. It lost $38.8M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$9.3MView ↗
8-K, filed Oct 5, 2026
MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on…View ↗
8-K, filed Aug 31, 2026
Ms. Getz continued, “At the same time, we are implementing a broader initiative to strengthen our cost structure and position TELA Bio for…View ↗
8-K, filed Aug 4, 2026
On August 3, 2026, the Board of Directors (the “Board”) of TELA Bio, Inc. (the “Company”) determined that, Antony Koblish will no longer…View ↗
Growing. Revenue grew 2.7x in 4 years, from $29.5M in FY2021 to $80.3M in FY2025, about 28% a year.
Broader PRS product line
The latest report describes OviTex PRS with three configurations, including permanent and resorbable polymer options; the older report describes the portfolio without these configurations.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 25, 2026Our second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (“OviTex PRS”), which we first commercialized in the U.S. in May…View ↗
Our second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, (“OviTex PRS”) which we first commercialized in the U.S. in May…View ↗
New distribution products
The older report describes a surgical wash distributed through a partner and a wound-care product launched with a development partner. The latest report says distribution rights to the wound-care product were sold and describes a hernia fixation device distribution agreement.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 25, 2026We also continue to expand our service offerings and diversify our supplier base as we continue to create a soft tissue restoration…View ↗
Historically, we have sought to expand our service offerings beyond our OviTex and OviTex PRS products through commercial partnerships to…View ↗
Competes with Bard, Becton, Dickinson and, Allergan, AbbVie, MTF Biologics, Novadaq, RTI Surgical, and Integra Lifesciences
10-K for FY2025, filed Mar 25, 2026In the hernia repair market, our primary competitors are Bard, a subsidiary of Becton, Dickinson and Company, which produces Phasix and…View ↗
Loading...